The FDA is adding to its previous directives to opioid use disorder (OUD) drug developers by expanding the options for suitable clinical effectiveness end points.
A new final guidance, titled “Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Treatment,” follows one released in February 2019 outlining the FDA’s position on drug development and trial design with regard to depot buprenorphine products.